Robert Huddart

31.9k total citations · 9 hit papers
388 papers, 14.9k citations indexed

About

Robert Huddart is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Robert Huddart has authored 388 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Surgery, 173 papers in Pulmonary and Respiratory Medicine and 70 papers in Oncology. Recurrent topics in Robert Huddart's work include Testicular diseases and treatments (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Prostate Cancer Diagnosis and Treatment (67 papers). Robert Huddart is often cited by papers focused on Testicular diseases and treatments (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Prostate Cancer Diagnosis and Treatment (67 papers). Robert Huddart collaborates with scholars based in United Kingdom, United States and Canada. Robert Huddart's co-authors include David P. Dearnaley, A. Horwich, A. Norman, Alan Horwich, Janet Shipley, Emma Hall, Vincent Khoo, Chris Parker, Rosalind A. Eeles and J. Nicholls and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Robert Huddart

375 papers receiving 14.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

2007 686 citations David P. Dearnaley, Robert Huddart et al. profile →
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

2012 617 citations Nicholas D. James, Syed A. Hussain et al. profile →
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

2018 397 citations S. Hafeez, Robert Huddart et al. profile →
Stereotactic body radiotherapy for oligometastases

2012 374 citations Alison Tree, Vincent Khoo et al. profile →
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

2014 344 citations David P. Dearnaley, Vincent Khoo et al. profile →
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2021 309 citations Robert Huddart, Yohann Loriot et al. Annals of Oncology profile →
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. profile →
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 99 citations Daniel M. Berney, Gedske Daugaard et al. Annals of Oncology profile →
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

2024 74 citations Robert Huddart, Yohann Loriot et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Robert Huddart

Since Specialization

Citations

This map shows the geographic impact of Robert Huddart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Huddart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Huddart more than expected).

Fields of papers citing papers by Robert Huddart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Huddart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Huddart. The network helps show where Robert Huddart may publish in the future.

Co-authorship network of co-authors of Robert Huddart

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Huddart. A scholar is included among the top collaborators of Robert Huddart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Huddart. Robert Huddart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study 2025 ·Clinical Genitourinary Cancer ·Nobuaki Matsubara, Yohann Loriot, Earle F. Burgess, Se Hoon Park, Robert Huddart, Ja Hyeon Ku, Ben Tran, Jian Huang, Yu‐An Huang, Kazuo Nishimura, Nobuaki Shimizu, (unknown), Wei Xue, (unknown), (unknown), (unknown), Spyros Triantos, Arlene O. Siefker‐Radtke	1
2	HER2 and urothelial carcinoma: current understanding and future directions 2025 ·Nature Reviews Urology ·Daniele Raggi, (unknown), Filippo Pederzoli, Alberto Martini, (unknown), Omar Alhalabi, Peter H. O’Donnell, Jeffrey S. Ross, Shilpa Gupta, Ashish M. Kamat, Bishoy M. Faltas, Peter C. Black, Philippe E. Spiess, Petros Grivas, Jianjun Gao, Andrea B. Apolo, Robert Huddart, Andrea Necchi, Matthew D. Galsky	1
3	1212: Assessing a unique bladder preparation protocol for patients undergoing prostate cancer radiotherapy 2024 ·Radiotherapy and Oncology ·(unknown), S. Alexander, Helen Barnes, (unknown), Robert Huddart, Trina Herbert, (unknown), (unknown), (unknown), (unknown), (unknown), Alison Tree, (unknown), (unknown), (unknown), H. McNair	1
4	697P The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors 2024 ·Annals of Oncology ·(unknown), (unknown), Robert Huddart, Dianne Nicol, (unknown), (unknown), Netty Kinsella, Claudia A. Kirk, (unknown), Máire Drain	1
5	FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro). 2024 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert Huddart, Earle F. Burgess, (unknown), Neil Beeharry, Shibu Thomas, Nicole L. Stone, Kris Deprince, Spyros Triantos, Woonyoung Choi	0
6	Cognitive function in long-term testicular cancer survivors: impact of modifiable factors 2024 ·JNCI Cancer Spectrum ·Paul C. Dinh, Patrick O. Monahan, Chunkit Fung, Howard D. Sesso, Darren R. Feldman, David J. Vaughn, Robert J. Hamilton, Robert Huddart, Neil E. Martin, Christian Kollmannsberger, Sandra K. Althouse, Lawrence H. Einhorn, Robert D. Frisina, James C. Root, Tim A. Ahles, Lois B. Travis	2
7	Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy 2023 ·Physics and Imaging in Radiation Oncology ·(unknown), S. Alexander, Trina Herbert, Robert Huddart, M. Ingle, Adam Mitchell, Simeon Nill, Uwe Oelfke, Alex Dunlop, S. Hafeez	1
8	Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer 2023 ·Clinical Oncology ·L. Philipps, Núria Porta, Nicholas D. James, Robert Huddart, (unknown), Leslie K. Ballas, Emma Hall	2
9	Understanding the health-related quality of life and treatment-related side-effects in patients who have been in remission from testicular cancer for 12–24 months 2023 ·SHILAP Revista de lepidopterología ·Walter Cazzaniga, Netty Kinsella, (unknown), Masood Moghul, Louis Fox, Mieke Van Hemelrijck, Alison Reid, Robert Huddart, David Nicol	1
10	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial 2022 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Syed A. Hussain, J.F. Lester, Richard A. Jackson, (unknown), (unknown), Anthony Elliott, Simon J. Crabb, Robert Huddart, Naveen Vasudev, Alison Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark Linch, Irbaz Bin Riaz, James W.F. Catto, Thomas Powles, Robert J. Jones	20
11	Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy 2022 ·Cancer Medicine ·(unknown), Matthew R. Trendowski, Emma Wilkinson, (unknown), Paul C. Dinh, Megan M. Shuey, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Robert Huddart, Neil E. Martin, Victoria A. Sanchez, Robert D. Frisina, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis, M. Eileen Dolan	11
12	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE) 2021 ·Clinical Cancer Research ·Simon J. Crabb, Sarah Danson, James W.F. Catto, Syed A. Hussain, (unknown), (unknown), Nichola Downs, Ellice Marwood, (unknown), Geoff Saunders, (unknown), Amy Whitehead, (unknown), Naveed Sarwar, Deborah Enting, Alison Birtle, Bernadette Johnson, Robert Huddart, Gareth Griffiths	17
13	Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance 2020 ·BMJ Open ·S. Hafeez, (unknown), (unknown), K. Warren-Oseni, Vibeke Hansen, H. McNair, Elizabeth Miles, Rebecca Lewis, Emma Hall, Robert Huddart	21
14	Patterns of recurrence after prostate bed radiotherapy 2019 ·Radiotherapy and Oncology ·Douglas Brand, (unknown), David P. Dearnaley, Rosalind A. Eeles, Robert Huddart, Vincent Khoo, Julia Murray, Yae‐Eun Suh, Alison Tree, Nicholas van As, Chris Parker	15
15	Runs of homozygosity and testicular cancer risk 2019 ·Andrology ·Chey Loveday, Amit Sud, Kevin Litchfield, Max Levy, (unknown), Peter Broderick, Zsofia Kote‐Jarai, Alison M. Dunning, Kenneth Muir, Julian Peto, Rosalind A. Eeles, Douglas F. Easton, Darshna Dudakia, Nick Orr, Nora Pashayan, (unknown), Robert Huddart, Richard S. Houlston, Clare Turnbull	4
16	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma 2015 ·Clinical Cancer Research ·Duncan C. Gilbert, Reem Al‐Saadi, Khin Thway, Ian Chandler, Daniel M. Berney, Rhian Gabe, Sally Stenning, Joan Sweet, Robert Huddart, Janet Shipley	18
17	18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC trial TE22 - The NCRI testis tumour clinical study group 2007 ·UCL Discovery (University College London) ·Robert Huddart, (unknown), Anwar R. Padhani, (unknown), G.M. Mead, (unknown), P. Vasey, (unknown), Jennifer Logue, Gedske Daugaard, (unknown), (unknown), (unknown), (unknown)	5
18	¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group 2007 ·Journal of Clinical Oncology ·Robert Huddart, Michael O’Doherty, Anwar R. Padhani, Gordon Rustin, Graham M. Mead, Johnathan Joffe, P. Vasey, Stephen Harland, John Logue, Gedske Daugaard, Sharon F. Hain, S Kirk, Jane E. Mackewn, Sally Stenning	68
19	Phase II multicenter study of imatinib in patients with chemorefractory germ cell tumors that express c-kit. 2007 ·Cancer Research ·(unknown), Xavier García del Muro, Robert Huddart, Jorge Aparicio, Luis Paz‐Ares, Marcelo Sánchez, David Olmos, (unknown), (unknown)	12
20	Target Volume Definition for Intensity Modulated Whole Pelvic Radiotherapy (IMWPRT) 2005 ·International Journal of Radiation OncologyBiologyPhysics ·J. Staffurth, Elizabeth Adams, Stephen Breen, Aslam Sohaib, Robert Huddart, David P. Dearnaley	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact